

**We claim:**

1. ~~A method of~~ Use of a SMARCA2/4 degrader in the manufacture of a medicament for treating a disease or disorder in a subject in need thereof who is identified to respond to the treatment, wherein the method of ~~comprising:~~

~~——a) identifying the subject as a responder to treatment with at least one SMARCA2/4 degraders via the steps of~~ comprises:

- i. isolating a biological sample from the subject;
- ii. determining the presence of tumor specific alterations; and
- iii. identifying the subject as a responder to said treatment if at least one of the tumor specific alterations is present; ~~and~~

~~b) administering a therapeutically effective amount of at least one SMARCA2/4 degrader to the subject who is identified to respond to the treatment, thereby treating the disease or disorder.~~

2. The ~~method~~ use of claim 1, wherein

the subject is identified as a moderate responder to the treatment with the SMARCA2/4 degraders if one tumor specific alteration is present; or

the subject is identified as a high responder to the treatment with the SMARCA2/4 degraders if at least two tumor specific alterations are present.


3. ~~The method of any one of claims 1 to 2, wherein the tumor specific alteration is:~~

~~——a mutation, an amplification, or an overexpression of Androgen Receptor (AR) gene;~~

~~——a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or~~

~~——a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.~~

4. ~~The method of claim 1 or 2, wherein the SMARCA2/4 degrader is a compound of formula (I):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;~~


~~wherein,~~

~~R<sub>1</sub> is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, COOR<sub>a</sub>, CON(R<sub>a</sub>)<sub>2</sub>, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, ONa, COOR<sub>a</sub>, or OCOR<sub>a</sub>; wherein R<sub>a</sub> at each occurrence is hydrogen or alkyl;~~

~~R<sub>2</sub> is NR<sub>3</sub>R<sub>4</sub> or OR<sub>3</sub>; wherein, R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or alkyl;~~

~~Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;~~


~~L is a linker with a chemical structure of:~~



~~wherein,~~

~~the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);~~


- ~~R<sub>6</sub> is hydrogen or alkyl;~~
- ~~R<sub>6</sub> is alkyl;~~
- ~~'n' is 0 to 10 and 'p' is 1 to 5;~~
- ~~Targeting Ligand (TL) is~~



~~wherein,~~


- ~~R<sub>6</sub> is hydrogen, alkyl, acyl, or haloalkyl;~~
- ~~R<sub>7</sub> is —O R<sub>5</sub> or halo; wherein R<sub>5</sub> is hydrogen, alkyl, acyl, or Na; and~~
- ~~R<sub>8</sub> is hydrogen or alkyl.~~

~~5. The method of claim 4, wherein the SMARCA2/4 degrader is a compound of formula (IA):~~




~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

~~6. The method of claim 4, wherein the SMARCA2/4 degrader is a compound of formula (IB):~~




~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

7. ~~The method of claim 4, wherein the SMARCA2/4 degrader is a compound of formula (IC):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

8. ~~The method of claim 12, wherein the SMARCA2/4 degrader is a compound of formula (D):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

9. ~~The method of claim 1, wherein the disease is a prostate disease.~~

10. ~~The method of claim 9, wherein the prostate disease is a prostate cancer.~~

11. ~~The method of claim 10, wherein the prostate cancer is a castration-resistant prostate cancer.~~

12. ~~The method of claim 1, wherein the subject has undergone castration.~~

13. ~~The method of claim 1, wherein the subject has undergone anti-androgen therapy.~~


~~3~~ 14. A Use of a SMARCA2/4 degrader in a method of selecting selection of a patient subject identified to respond to a treatment with of prostate cancer for treatment with a SMARCA2/4 degrader, comprising wherein the method comprises:

- a) isolating a biological sample from the patient subject;
- b) determining a presence of at least one tumor specific alteration in the biological sample; and
- c) selecting identifying the patient subject as a responder to the treatment of prostate cancer if with at least one of the tumor specific alterations is present in the sample for the treatment with the SMARCA2/4 degrader; and
- ~~—— d) administering a therapeutically effective amount of at least one SMARCA2/4 degrader to the selected patient.~~

4 15. The method use of any one of claims 1 to 3 14, wherein the tumor specific alteration is:

- a mutation, an amplification, or an overexpression of Androgen Receptor (AR) gene;
- a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or
- a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.

~~16. The method of claim 14, wherein the SMARCA2/4 degrader is a compound of formula (I):~~




- ~~—— or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;~~
- ~~—— wherein,~~
- ~~—— R<sub>4</sub> is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, COOR<sub>a</sub>, CON(R<sub>a</sub>)<sub>2</sub>, or aryl; wherein the aryl is optionally substituted independently with at~~

~~least one of hydroxy, alkoxy, halo, alkyl, amino, -ONa, -COOR<sub>a</sub>, or -OCOR<sub>a</sub>; wherein R<sub>a</sub> at each occurrence is hydrogen or alkyl;~~

~~— R<sub>2</sub> is -NR<sub>3</sub>R<sub>4</sub> or -OR<sub>3</sub>; wherein, R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or alkyl;~~

~~— Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;~~

~~— L is a linker with a chemical structure of:~~



wherein,


~~— the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);~~

~~— R<sub>b</sub> is hydrogen or alkyl;~~

~~— R<sub>c</sub> is alkyl;~~

~~— 'n' is 0 to 10 and 'p' is 1 to 5;~~

~~— Targeting Ligand (TL) is:~~




wherein,

— ~~R<sub>6</sub> is hydrogen, alkyl, acyl, or haloalkyl;~~

— ~~R<sub>7</sub> is —O—R<sub>5</sub> or halo; wherein R<sub>5</sub> is hydrogen, alkyl, acyl, or Na; and~~


— ~~R<sub>8</sub> is hydrogen or alkyl.~~

17. ~~The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (IA):~~




~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

18. ~~The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (IB):~~




~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

19. ~~The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (IC):~~



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

~~20. The method of claim 16, wherein the SMARCA2/4 degrader is a compound of formula (ID):~~



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.


~~21. The method of claim 14, wherein the prostate cancer is a castration-resistant prostate cancer.~~

~~22. The method of claim 14, wherein the patient has undergone castration or anti-androgen therapy.~~

~~23. A method of inhibiting proliferation of prostate cancer cells in a subject in need thereof, comprising a step of contacting the prostate cancer cells with at least one SMARCA2/4 degrader.~~

~~24. The method of claim 23, wherein the step of contacting comprises administering a therapeutically effective amount of at least one SMARCA2/4 degrader to the subject.~~

5 ~~25. The method use of any one of claims 1 to 4 23 to 24, wherein the SMARCA2/4 degrader is a compound of formula (I):~~



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


wherein,

$R_1$  is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl,  $-\text{COOR}_a$ ,  $-\text{CON}(\text{R}_a)_2$ , or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino,  $-\text{ONa}$ ,  $-\text{COOR}_a$ , or  $-\text{OCOR}_a$ ; wherein  $R_a$  at each occurrence is hydrogen or alkyl;

$R_2$  is  $-\text{NR}_3\text{R}_4$  or  $-\text{OR}_3$ ; wherein,  $R_3$  and  $R_4$  are independently hydrogen or alkyl;

Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

L is a linker with the chemical structure of:



wherein,


the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

$R_b$  is hydrogen or alkyl;

$R_c$  is alkyl;

'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is:







wherein,

R<sub>6</sub> is hydrogen, alkyl, acyl, or haloalkyl;

R<sub>7</sub> is -O-R<sub>5</sub> or halo; wherein R<sub>5</sub> is hydrogen, alkyl, acyl, or Na; and


R<sub>8</sub> is hydrogen or alkyl.

26. ~~The method of claim 25, wherein SMARCA2/4 degrader is a compound of formula (IA), (IB), (IC) or (ID):~~




~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

6. The use of claim 5, wherein the SMARCA2/4 degrader is a compound of formula (IA)




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

7. The use of claim 5, wherein the SMARCA2/4 degrader is a compound of formula (IB)




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

8. The use of claim 5, wherein the SMARCA2/4 degrader is a compound of formula (IC):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

9. The use of claim 5, wherein the SMARCA2/4 degrader is a compound of formula (ID)



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

~~27. The method of claim 23, wherein the prostate cancer cells comprise a castration-resistant prostate cancer.~~

~~28. The method of claim 23, wherein the prostate cancer cells comprise a prostate tumor.~~

~~29. The method of claim 23, wherein the subject has undergone castration.~~







~~30. The method of claim 23, wherein the subject has undergone anti-androgen therapy.~~






10 ~~34.~~ The ~~method~~ use of any one of claims 1 to 12 ~~30~~, wherein the SMARCA2/4 degrader is a compound with the chemical structure of:






| Compound No | Structure |
|-------------|-----------|
| 1.          |           |






|    |       |
|----|-------|
| 2. | <br>; |
| 3. | <br>; |
| 4. | <br>; |
| 5. | <br>; |




|     |                                                                                          |
|-----|------------------------------------------------------------------------------------------|
| 6.  | <chem>Nc1nc(NC2CCNCC2C(=O)NCCOCC(=O)Nc3c4c(cnc3=O)C(=O)NCC4=O)c5ccccc5O</chem> ;         |
| 7.  | <chem>Nc1nc(NC2CCNCC2C(=O)NCCOC(F)(F)FCC(=O)Nc3c4c(cnc3=O)C(=O)NCC4=O)c5ccccc5O</chem> ; |
| 8.  | <chem>Nc1nc(NC2CCN(C2)C(=O)NCCOCC(=O)Nc3c4c(cnc3=O)C(=O)NCC4=O)c5ccccc5O</chem> ;        |
| 9.  | <chem>Nc1nc(NC2CCN(C2)C(=O)NCCOCC(=O)Nc3c4c(cnc3=O)C(=O)NCC4=O)c5ccccc5O</chem> ;        |
| 10. | <chem>Nc1nc(NC2CCNCC2C(=O)NCCOCC(=O)Nc3c4c(cnc3=O)C(=O)NCC4=O)c5ccccc5O</chem> ;         |
| 11. | <chem>Nc1nc(NC2CCN(C2)C(=O)NCCOCC(=O)Nc3c4c(cnc3=O)C(=O)NCC4=O)c5ccccc5O</chem> ;        |





|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 12. |    |
| 13. |    |
| 14. |    |
| 15. |   |
| 16. |  |
| 17. |  |

|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 18. | <br>;   |
| 19. | <br>;   |
| 20. | <br>;   |
| 21. | <br>;  |
| 22. | <br>; |





|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 23. | <br>;   |
| 24. | <br>;   |
| 25. | <br>;  |
| 26. | <br>; |
| 27. | <br>; |





|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 28. | <br>;   |
| 29. | <br>;   |
| 30. | <br>;   |
| 31. | <br>;  |
| 32. | <br>; |





|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 33. | <br>;   |
| 34. | <br>;   |
| 35. | <br>; |





|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 36. | <br>;   |
| 37. | <br>;  |
| 38. | <br>; |
| 39. | <br>; |





|     |       |
|-----|-------|
| 40. | <br>; |
| 41. | <br>; |
| 42. | <br>; |
| 43. | <br>; |
| 44. | <br>; |

|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 45. | <br>;   |
| 46. | <br>;   |
| 47. | <br>;  |
| 48. | <br>; |






|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 49. | <br>;   |
| 50. | <br>;   |
| 51. | <br>;  |
| 52. | <br>; |





|     |                                                                                           |
|-----|-------------------------------------------------------------------------------------------|
| 53. | <br>;   |
| 54. | <br>;   |
| 55. | <br>;  |
| 56. | <br>; |





|             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 57. and 58. |  <p>Chemical structure of Isomer-1 and Isomer-2. The molecule features a 2-aminopyrimidin-5-yl group connected via a piperazine ring to a chiral amide. The amide is further connected to a 2-hydroxy-4-methyl-5-(4-(2-methyl-1,3,4-thiazol-5-yl)phenyl)pyrrolidine-3-carboxamide moiety. The structure is shown with a semicolon (;) indicating a pair of enantiomers.</p> <p>Isomer-1 and Isomer-2</p> |
| 59.         |  <p>Chemical structure of compound 59. The molecule features a 2-aminopyrimidin-5-yl group connected via a piperazine ring to a chiral amide. The amide is further connected to a 2-acetoxy-4-methyl-5-(4-(2-methyl-1,3,4-thiazol-5-yl)phenyl)pyrrolidine-3-carboxamide moiety. The structure is shown with a semicolon (;) indicating a pair of enantiomers.</p>                                        |
| 60.         |  <p>Chemical structure of compound 60. The molecule features a 2-aminopyrimidin-5-yl group connected via a piperazine ring to a chiral amide. The amide is further connected to a 2-acetoxy-4-methyl-5-(4-(2-methyl-1,3,4-thiazol-5-yl)phenyl)pyrrolidine-3-carboxamide moiety. The structure is shown with a semicolon (;) indicating a pair of enantiomers.</p>                                      |
| 61.         |  <p>Chemical structure of compound 61. The molecule features a 2-aminopyrimidin-5-yl group connected via a piperazine ring to a chiral amide. The amide is further connected to a 2-hydroxy-4-methyl-5-(4-(2-methyl-1,3,4-thiazol-5-yl)phenyl)pyrrolidine-3-carboxamide moiety. The structure is shown with a semicolon (;) indicating a pair of enantiomers.</p>                                      |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 62. |    |
| 63. |    |
| 64. |  |
| 65. |  |

|     |       |
|-----|-------|
| 66. | <br>; |
| 67. | <br>; |
| 68. | <br>; |
| 69. | <br>; |
| 70. | <br>; |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 71. |    |
| 72. |    |
| 73. |   |
| 74. |  |
| 75. |  |

|             |                                                                                                                                             |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| 76.         |                                                           |
| 77. and 78. |  <p style="text-align: center;">Isomer-1 and Isomer-2</p> |
| 79.         |                                                          |
| 80.         |                                                         |

|             |                                                                                                              |
|-------------|--------------------------------------------------------------------------------------------------------------|
| 81.         | <br>;                      |
| 82.         | <br>;                      |
| 83. and 84. | <br>Isomer-1 and Isomer-2 |
| 85.         | <br>;                    |

|     |                                                                                              |
|-----|----------------------------------------------------------------------------------------------|
| 86. | <br><chem>Nc1cc(N2CCN(CC2)CCNC(=O)C(C)(C)C(=O)N[C@@H]3C[C@H](O)CN3C(=O)C(C)C)cc(O)c1</chem>  |
| 87. | <br><chem>Nc1cc(N2CCN(CC2)CCNC(=O)C(C)(C)C(=O)N[C@@H]3C[C@H](O)CN3C(=O)C(C)C)cc(O)c1</chem>  |
| 88. | <br><chem>Nc1cc(N2CCN(CC2)CCNC(=O)C(C)(C)C(=O)N[C@@H]3C[C@H](O)CN3C(=O)C(C)C)cc(F)c1F</chem> |
| 89. | <br><chem>Nc1cc(N2CCN(CC2)CCNC(=O)C(C)(C)C(=O)N[C@@H]3C[C@H](O)CN3C(=O)C(C)C)cc(Cl)c1</chem> |

|     |  |
|-----|--|
| 90. |  |
| 91. |  |
| 92. |  |
| 93. |  |

|     |       |
|-----|-------|
| 94. | <br>; |
| 95. | <br>; |
| 96. | <br>; |
| 97. | <br>; |


|      |       |
|------|-------|
| 98.  | <br>; |
| 99.  | <br>; |
| 100. | <br>; |
| 101. | <br>; |

|      |       |
|------|-------|
| 102. | <br>; |
| 103. | <br>; |
| 104. | <br>; |
| 105. | <br>; |

|      |       |
|------|-------|
| 106. | <br>; |
| 107. | <br>; |
| 108. | <br>; |
| 109. | <br>; |

|      |       |
|------|-------|
| 110. | <br>; |
| 111. | <br>; |
| 112. | <br>; |
| 113. | <br>; |

|      |  |
|------|--|
| 114. |  |
| 115. |  |
| 116. |  |
| 117. |  |




or a pharmaceutically acceptable salt or a stereoisomer thereof.

32. ~~— A method of selecting a subject with prostate disease for treatment with a SMARCA2/4 degrader, comprising:~~

- ~~a) isolating a biological sample from the subject;~~
- ~~b) determining a presence of at least one tumor specific alteration in the biological sample;~~
- ~~c) selecting the patient with at least one tumor specific alteration present in the sample for the treatment with the SMARCA2/4 degrader; and~~
- ~~d) administering a therapeutically effective amount of at least one SMARCA2/4 degrader to the selected subject.~~

33. ~~— The method of claim 32, wherein the tumor specific alteration is:~~  
~~a mutation, an amplification, or an overexpression of Androgen Receptor (AR) gene;~~  
~~a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or~~  
~~a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.~~

34. ~~— The method of claim 32, wherein SMARCA2/4 degrader is a compound of formula (I):~~



— or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


— wherein,

—  $R_1$  is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl,  $\text{COOR}_a$ ,  $\text{CON}(\text{R}_a)_2$ , or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino,  $\text{ONa}$ ,  $\text{COOR}_a$ , or  $\text{OCOR}_a$ ; wherein  $\text{R}_a$  at each occurrence is hydrogen or alkyl;

—  $\text{R}_2$  is  $\text{NR}_3\text{R}_4$  or  $\text{OR}_3$ ; wherein,  $\text{R}_3$  and  $\text{R}_4$  are independently hydrogen or alkyl;

— Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

— L is a linker with a chemical structure of:



wherein,


— the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

—  $\text{R}_b$  is hydrogen or alkyl;

—  $\text{R}_c$  is alkyl;

— 'n' is 0 to 10 and 'p' is 1 to 5;

— Targeting Ligand (TL) is:







wherein,

— ~~R<sub>6</sub> is hydrogen, alkyl, acyl, or haloalkyl;~~

— ~~R<sub>7</sub> is —O—R<sub>5</sub> or halo; wherein R<sub>5</sub> is hydrogen, alkyl, acyl, or Na; and~~

— ~~R<sub>8</sub> is hydrogen or alkyl.~~

35. — ~~The method of claim 34, wherein SMARCA2/4 degrader is a compound of formula (IA), (IB), (IC) or (ID):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

11. The use of claim 1, wherein the disease is a prostate disease.

12 36. The ~~method~~ use of claim 1 32, wherein the prostate disease is a prostate cancer.

13 37. The ~~method~~ use of claim 1 32, wherein the prostate cancer is a castration-resistant prostate cancer.

14 38. The ~~method~~ use of claim 1 32, wherein the subject has undergone castration or anti-androgen therapy.

15. Use of a SMARCA2/4 degrader in an in-vitro method of inhibiting proliferation of prostate cancer cells having at least one tumor specific alteration, comprising a step of contacting the prostate cancer cells with at least one SMARCA2/4 degraders.


16. The use of claim 15, wherein the prostate cancer cells comprise a castration-resistant prostate cancer or a prostate tumor.

17. The use of claim 15, wherein the tumor specific alteration is:  
a mutation, an amplification, or an overexpression of Androgen Receptor (AR) gene;

a loss of function or a deleterious mutation in phosphatase and tensin homolog (PTEN); or

a genomic rearrangement that results in a translocation between a TMPRSS2 gene and an ERG gene.

18. The use of any one of claims 15 to 17, wherein the SMARCA2/4 degrader is a compound of formula (I):



\_\_\_\_\_ or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;


\_\_\_\_\_ wherein,

\_\_\_\_\_  $R_1$  is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl,  $-\text{COOR}_a$ ,  $-\text{CON}(\text{R}_a)_2$ , or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino,  $-\text{ONa}$ ,  $-\text{COOR}_a$ , or  $-\text{OCOR}_a$ ; wherein  $R_a$  at each occurrence is hydrogen or alkyl;

\_\_\_\_\_  $R_2$  is  $-\text{NR}_3\text{R}_4$  or  $-\text{OR}_3$ ; wherein,  $R_3$  and  $R_4$  are independently hydrogen or alkyl;

\_\_\_\_\_ Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;

\_\_\_\_\_ L is a linker with the chemical structure of:



\_\_\_\_\_ wherein,


\_\_\_\_\_ the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

\_\_\_\_\_  $R_b$  is hydrogen or alkyl;

\_\_\_\_\_  $R_c$  is alkyl;

\_\_\_\_\_ 'n' is 0 to 10 and 'p' is 1 to 5;

\_\_\_\_\_ Targeting Ligand (TL) is:







wherein,

R<sub>6</sub> is hydrogen, alkyl, acyl, or haloalkyl;

R<sub>7</sub> is -O-R<sub>5</sub> or halo; wherein R<sub>5</sub> is hydrogen, alkyl, acyl, or Na; and

R<sub>8</sub> is hydrogen or alkyl.


19. The use of claim 18, wherein the SMARCA2/4 degrader is a compound of formula (IA), (IB), (IC) or (ID):



or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

39. ~~The method of claim 32, wherein the subject has undergone anti-androgen therapy.~~

40. ~~A compound for use in method of selecting the subject with prostate cancer wherein the compound is represented by compound of formula (I):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof;~~


~~wherein,~~

~~R<sub>1</sub> is hydrogen, halo, alkyl, alkenyl, alkoxy, hydroxy, hydroxyalkyl, COOR<sub>a</sub>, CON(R<sub>a</sub>)<sub>2</sub>, or aryl; wherein the aryl is optionally substituted independently with at least one of hydroxy, alkoxy, halo, alkyl, amino, ONa, COOR<sub>a</sub>, or OCOR<sub>a</sub>; wherein R<sub>a</sub> at each occurrence is hydrogen or alkyl;~~

~~R<sub>2</sub> is NR<sub>3</sub>R<sub>4</sub> or OR<sub>3</sub>; wherein, R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or alkyl;~~

~~Ring A is heterocyclic ring optionally substituted independently with at least one of hydroxy, halo or alkyl;~~

~~L is a linker with a chemical structure of:~~



wherein,


the left side of the linker is attached with ring A and the right side of the linker is attached with Targeting Ligand (TL);

$R_6$  is hydrogen or alkyl;

$R_7$  is alkyl;

'n' is 0 to 10 and 'p' is 1 to 5;

Targeting Ligand (TL) is




wherein,

$R_6$  is hydrogen, alkyl, acyl, or haloalkyl;

$R_7$  is  $O-R_5$  or halo; wherein  $R_5$  is hydrogen, alkyl, acyl, or Na; and


$R_8$  is hydrogen or alkyl.

41. The compound for use according to claim 40, wherein the compound is represented by compound of formula (IA):




or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

42. The compound for use according to claim 40, wherein the compound is represented by compound of formula (IB):




~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

43.—~~The compound for use according to claim 40, wherein the compound is represented by compound of formula (IC):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~

44.—~~The compound for use according to claim 40, wherein the compound is represented by compound of formula (ID):~~



~~or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.~~